Jeffrey M. Leiden - 01 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Executive Chairman, Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2023
Net transactions value
-$1,137,196
Form type
4
Filing time
03 Feb 2023, 15:53:40 UTC
Previous filing
27 Jul 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +31,462 +1298% $0.000000 33,885 01 Feb 2023 Direct F1
transaction VRTX Common Stock Award $0 +34,890 +103% $0.000000 68,775 01 Feb 2023 Direct F2
transaction VRTX Common Stock Award $0 +10,226 +15% $0.000000 79,001 01 Feb 2023 Direct F3
transaction VRTX Common Stock Tax liability $1,137,196 -3,578 -4.5% $317.83 75,423 02 Feb 2023 Direct
holding VRTX Common Stock 440 01 Feb 2023 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/24/2023.
F3 Restricted stock unit award that fully vested upon grant.